Drug Trial Radar · NCT00098293
Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine
Last checked: Nov 20, 2026Latest source record: Oct 9, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
916
Actual
Start
Nov 2004
Primary completion
Apr 2007
Study completion Dec 2012
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- Dec 7, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The goal of this study is to compare the safety and efficacy of maraviroc (UK-427,857) versus efavirenz, when each are combined with two other antiretroviral agents, in patients who are previously naive to antiretroviral therapy. This study will involve approximately 200 centers from around the world to achieve a total randomized subject population of 1071 subjects. Patients will be randomly assigned to one of three groups: maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily), Maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily) or efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily). The study will enroll over approximately an 18 month period (5 months Phase 2b run-in, 13 months Phase 3) with 96 weeks of treatment. This may be extended for an additional 3 years depending on the results at 96 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40, 48, 60, 72, 84 and 96. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 48 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24, 48 and 96. A computerized tomography (CT) scan will also be performed, at selected centers, at study entry and week 96. Patients will be asked to complete a symptom distress questionnaire at study entry, weeks 12, 24, 48 and 96.
Conditions
- HIV-1
Interventions
Maraviroc + Zidovudine/LamivudineDrug
maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Efavirenz + Zidovudine/LamivudineDrug
efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Maraviroc (UK-427,857) + Zidovudine/LamivudineDrug
maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Viral Load of Less Than 400 Copies/Milliliter [Copies/mL] and Less Than 50 Copies/mL of Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) at Week 48 for Full Analysis Set (FAS) PopulationTime frame: Week 48
- Percentage of Participants With Viral Load of Less Than 400 Copies/mL and Less Than 50 Copies/mL of HIV-1 RNA at Week 48 for Per Protocol (PP) PopulationTime frame: Week 48
Locations
144 sites in 14 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Birmingham, Alabama
Pfizer Investigational Site
Beverly Hills, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Newport Beach, California
Pfizer Investigational Site
Oakland, California
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Aurora, Colorado
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami, Florida
Pfizer Investigational Site
Miami Beach, Florida
Pfizer Investigational Site
Orlando, Florida
Pfizer Investigational Site
Sarasota, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Chicago, Illinois
Pfizer Investigational Site
Indianapolis, Indiana
Pfizer Investigational Site
Baltimore, Maryland
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Boston, Massachusetts
Pfizer Investigational Site
Springfield, Massachusetts
Pfizer Investigational Site
Omaha, Nebraska
Pfizer Investigational Site
Albany, New York
Pfizer Investigational Site
Brooklyn, New York
Pfizer Investigational Site
Flushing, New York
Pfizer Investigational Site
Manhasset, New York
Pfizer Investigational Site
New York, New York
Pfizer Investigational Site
Huntersville, North Carolina
Pfizer Investigational Site
Cincinnati, Ohio
Pfizer Investigational Site
Oklahoma City, Oklahoma
Pfizer Investigational Site
Oklahoma City, Oklahoma
Pfizer Investigational Site
Philadelphia, Pennsylvania
Pfizer Investigational Site
Columbia, South Carolina
Pfizer Investigational Site
Dallas, Texas
Showing 40 of 144 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.